Table 1 The basic characteristics of included studies
From: Prognostic value of microRNAs in patients with small cell lung cancer: a meta-analysis
Study ID | miRNA type | Prognosis | Resources | Follow-up time | miRNA panel | Influence | NOS | Region | Year |
|---|---|---|---|---|---|---|---|---|---|
Mancuso et al. [6] | miR-192 | OS | Tumor | 83 months | 1 | Oncogenic | 8 | Italy | 2016 |
miR-200c | OS | Tumor | 83 months | 1 | Oncogenic | 8 | |||
3-miRNA | OS | Tumor | 83 months | 3 | Oncogenic | 8 | |||
Cao et al. [7] | miR-886-3p | OS | Tumor | 120 months | 1 | Tumor suppressive | 8 | China | 2013 |
miR-886-3p | PFS | Tumor | 120 months | 1 | Tumor suppressive | 8 | |||
Zhou et al. [8] | miR-184 | PFS | Serum | 27 months | 1 | Tumor suppressive | 7 | China | 2015 |
miR-574-5p | PFS | Serum | 27 months | 1 | Oncogenic | 7 | |||
miR-574-5p | OS | Serum | 27 months | 1 | Oncogenic | 7 | |||
Liu et al. [9] | miRNA-7 | OS | Tumor | 50 months | 1 | Tumor suppressive | 8 | China | 2015 |
Li et al. [10] | miRNA-92b | PFS | Plasma | 30 months | 1 | Oncogenic | 6 | China | 2020 |
miR-375 | PFS | Plasma | 30 months | 1 | Oncogenic | 6 | |||
2-miRNA | PFS | Plasma | 30 months | 2 | Oncogenic | 6 | |||
2-miRNA | OS | Tumor | 120 months | 2 | Tumor suppressive | 9 | |||
Bi et al. [11] | 2-miRNA | PFS | Tumor | 120 months | 2 | Tumor suppressive | 9 | China | 2014 |
Ranade et al. [12] | miR-92a-2 | OS | Tumor | 80 months | 1 | Oncogenic | 8 | America | 2010 |